Overview:-
Uterine cancer is the kind of cancer in which abnormal cells are grown in female uterus that comprises of uterine tissue. The buildup cancer cells form malignant tumor in uterine region. It is one of the most frequent gynecologic malignancy among female cancer patients. There are two kinds of uterine cancer that are uterine sarcoma and endometrial cancer. Uterine sarcoma is rare cancer condition in which supporting tissues and muscles of the uterus are abnormally developed, whereas endometrial cancer is often curable and is caused due to uncontrolled growth of inner linings of uterus.
Request for Analysis of COVID-19 Impact on Uterine Cancer Drugs Market –
https://www.coherentmarketinsights.com/insight/request-sample/1745
There are various therapies for cancer treatment; however the most recommended therapy for uterine sarcomas treatment is chemotherapy. However, it may not be accessible in certain kinds of uterine sarcoma. Chemotherapy is often performed in the earlier stages of cancer in uterine sarcoma. Various chemotherapy drugs used in the treatment of uterine sarcoma include Epirubicin (Ellence), Liposomal doxorubicin (Doxil), Dacarbazine (DTIC), Docetaxel (Taxotere), Paclitaxel (Taxol) and among others. Moreover, for the treatment of endometrial cancer, U.S. Food and Drug Administration (FDA) approved the only drug named as Megestrol Acetate till March 2016. Thus, it is perceived that both types of uterine cancer could be diagnosed through Pap smear screening test, endometrial biopsy or colposcopy.
Market Drivers:-
The major factors such as increasing number of new targeted cancer drugs, increasing insurance coverage, and increasing funding for cancer research propelled the growth of the uterine cancer drugs market. For instance, in 2015, National Cancer Institute invested around US$ 4,480 million on cancer research including ovarian cancer, breast cancer, liver cancer, colorectal cancer, lung cancer, cervical cancer, uterine cancer and leukemia. Moreover, in 2014, American Cancer Society reported that, around US$ 87.8 billion were invested by U.S. on cancer research, in which around 44% was major accounting cost paid by private insurance companies.
Another factor to augment growth of the uterine cancer drugs market is increasing number of clinical trials conducted for treatment of uterine sarcoma and endometrial cancer. For Instance, in August 2017, the clinical trials database of the U.S. National Library of Medicine conveyed that, a New York based cancer treatment and research institute named as Memorial Sloan Kettering Cancer Center conducted two clinical trial to study and estimate uterine cancer. The two trials were consist of phase I clinical stage where the Selinexor (KPT-330) with Carboplatin and Paclitaxel was used for treating severe endometrial and ovarian cancers and the other one was Nivolumab immunotherapy in phase II study to treat recurrent or persistent uterine cancer.
Request PDF Brochure Report –
https://www.coherentmarketinsights.com/insight/request-pdf/1745
Various government and private research organizations got involved into research and development studies to develop effective drugs for the treatment of uterine sarcoma and endometrial cancer. Along with it increasing incidence rate of uterine cancer across the world expected boost in the uterine cancer drugs market growth in near future. For instance, January 2018, the American Cancer Society reported the number of new cases of uterine cancer in the U.S. that are to be diagnosed are around 63,230 with the death of around 11,350 women by uterine cancer in 2018. These estimations of diagnosed and death numbers includes both uterine sarcomas and endometrial cancers. It is also estimated that upto 8% of uterine body cancers are sarcomas. Endometrial cancer majorly affects post-menopausal women with the average age of 60 years. For Instance, in 2015, the Cancer Research UK stated that, the fourth most usual cancer among the women is uterine cancer with around 9,000 new cases in the U.K., which accounted for 5% of all new cancer cases in females in the UK in 2015.
Key Players:-
The major players operating in the uterine cancer drugs market consist of United Biotech Pvt Ltd, Actiza Pharmaceutical Private Limited, Par Pharmaceutical Companies, Inc., Merck & Company, Inc., Elder Pharmaceuticals Ltd, and others.
Uterine Cancer Drugs Market Taxonomy:
By Indication:
- Endometrial Cancer
- Uterine Sarcoma
By Product Type:
- Megestrol Acetate
- Dacarbazine (DTIC)
- Docetaxel (Taxotere)
- Gemcitabine (Gemzar)
- Epirubicin (Ellence)
- Paclitaxel (Taxol)
- Temozolomide (Temodar)
- Others
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Reasons to Purchase this Report
Current and future of global Uterine Cancer Drugs market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1745
Regional Analysis:-
The global uterine cancer drugs market is segmented on the basis of geographical region into North America, Latin America, Asia Pacific, Middle East, Africa and Europe. Thus, uterine cancer drugs market is anticipated to witness a significant growth in North America and Europe region, followed by Asia Pacific region. North America dominated the uterine cancer drugs market, due to its increasing rate of endometrial cancer cases. For instance, in January 2015, World Cancer Research Fund International published data findings of the International Agency for Research on Cancer 2014. It stated that the cases of endometrial cancer were reported around 53% and mostly found in developed economies including U.S., Poland, Norway, Luxemburg, and among others. Furthermore, the highest cases of endometrial cancer were found in Northern America and Europe and the lowest cases were found in Asia and Africa. For Instance, in April 2018, Journal of the National Cancer Institute published a data that reported North America, Northern and Eastern Europe had the highest rate of endometrial cancer incidence, whereas middle-income countries including India and South Africa had the lowest rate of cancer incidence.
As per World Health Organization (WHO), cervical cancer was found to be 4th most frequent type of cancer in women as per data findings of in 2018. It was estimated that around 530,000 new cases of cervical cancer were found in 2012, which was 7.9% of all female cancers. In 2015, WHO also reported that around 90% of deaths or 270,000 deaths caused by cervical cancer were occurred in middle-income and low-income countries. Furthermore, the developed economic countries such as North America and Europe have higher prevalence of endometrial cancer, owing to women lifestyles changes in these countries. Mostly, women aged with 50 years and above suffer from the prevalence of uterine cancer than other.
Major Point Answered in Uterine Cancer Drugs Market Research Study are:
What will be the progress rate of the Uterine Cancer Drugs Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Uterine Cancer Drugs Market across different regions?
Who are the major vendors dominating the Uterine Cancer Drugs industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Uterine Cancer Drugs Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
